Abstract #2370

Quantitative Imaging of Pharmacodynamics in a Phase 1 Clinical Study of the Vascular Disrupting Agent Crolibulin (EPC2407)

Andres M. Arias Lorza¹, William L. Read², Raoul Tibes³, Ronald L. Korn⁴, and Natarajan Raghunand^1,5

¹Department of Cancer Physiology, Moffitt Cancer Center, TAMPA, FL, United States, ²Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, United States, ³Perlmutter Cancer Center, NYU Langone Health, New York, NY, United States, ⁴Imaging Endpoints, LLC, Scottsdale, AZ, United States, ⁵Department of Oncologic Sciences, University of South Florida, Tampa, FL, United States

Diffusion and DCE-MRI were performed at baseline and 2-3 days following Crolibulin (EPC2407) treatment in a phase 1 clinical study of this vascular disrupting agent. ADC_w, K^trans, V_e, and V_p parameter maps were computed and co-registered across scan dates. Over 10 subjects there was an average of 44% decrease in mean tumor K^trans 2-3 days after initiation of therapy relative to baseline K^trans values. The decrease in whole-tumor K^trans was significantly greater in subjects who received 24 mg/m² drug relative to those who received 13 mg/m² Crolibulin. Voxel-wise analysis of changes in ADC_w, K^trans, V_e, and V_p will be presented.

This abstract and the presentation materials are available to members only; a login is required.

Join Here